PharmTech News

Articles

The new mechanism of action targets cholinergic receptors instead of the standard dopamine receptors.

FDA Approves Schizophrenia Treatment that Targets Cholinergic Receptors

Feliza Mirasol is the science editor for 

The approval of EBGLYSS (lebrikizumab-lbkz) by FDA puts a new biologic treatment for moderate-to-severe atopic dermatitis on the market for patients whose symptoms are not well controlled with topical treatments.

Lilly’s EBGLYSS Offers New First-Line Biologic Treatment for Atopic Dermatitis Following FDA Approval

 is a Life Science industry digital transformation consultant with over 38 years of experience in manufacturing process automation, digital transformation, CSV/CSA, Data Integrity, 21 

 Part 11 and Annex 11. He is a member of ISPE’s Data Integrity Special Interest Group (SIG) and is a senior industry consultant for 

. He has worked for and consulted with several companies, including Genentech, Roche, Bayer, Novartis, Gilead, and others. He travels the world to train industry personnel in the areas of his expertise, as well as to conduct data integrity audits.

The drug manufacturing ecosystem Pharma 4.0, a term coined in 2017 by the International Society for Pharmaceutical Engineers, promises a revolution across drug discovery, manufacturing, and supply chain logistics, ensuring drugs are delivered precisely when needed, and improving overall patient care.

Validating Pharma 4.0 for Smart Manufacturing

Lilly has added a $1 billion investment to increase biologics manufacturing at its Limerick, Ireland, site while unveiling its new $800 million facility in Kinsale.

Lilly’s $1.8 Billion Biologics Expansion Expected to Grow Manufacturing Footprint in Ireland

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

The company said this new commitment to its facility in Germany goes hand in hand with its recently announced ReciPredict, an initiative intended to streamline the product development cycle.

Recipharm Investment Will Enhance Oral Solid Development, GMP Pilot-Scale Suites

Novo Nordisk will use Korro Bio’s OPERA platform to develop RNA editing candidates for two targets to treat cardiometabolic diseases.

Korro Bio and Novo Nordisk Collaborate on Cardiometabolic Treatments

The approach makes use of clinical mass spectrometers that are already available in hospitals around the world.

University of Oxford Chemists Develop Method for Vaccine Authenticity Screening

Phase III trial results showed that Imfinzi (durvalumab in combination with chemotherapy reduced the risk of recurrence, progression, or death by 32% in patients with resectable non-small cell lung cancer before and after surgery.

AstraZeneca’s Imfinzi Gets Expanded Indication in Lung Cancer on FDA Approval

The completed acquisition of Morphic expands Lilly's immunology pipeline with Morphic's oral integrin therapies for treating inflammatory bowel disease.

Completion of $3.2 Billion Morphic Acquisition Expands Lilly’s IBD Portfolio

PiaSky (crovalimab) has previously been approved in countries such as the United States and Japan for monthly, subcutaneous use that may be self-administered with adequate training.

Bio/Pharma News